Avalyn Pharma Inc.

S-1 filed

Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for rare respiratory diseases, particularly pulmonary fibrosis. The company's pipeline includes AP01 and AP02, inhaled formulations of pirfenidone and nintedanib, respectively, for progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. AP03, a fixed-dose combination of both drugs, is advancing to Phase 1 trials. The IPO aims to fund clinical development and commercialization efforts, with shares expected to be listed on the Nasdaq Global Market under 'AVLN'. The company highlights potential advantages of inhaled therapies over oral treatments, including improved tolerability and efficacy.

DRS/A amended

Avalyn Pharma Inc. is conducting its initial public offering (IPO) of common stock, aiming to list on the Nasdaq Global Market under the symbol 'AVLN.' The company focuses on developing inhaled therapies for rare respiratory diseases, particularly pulmonary fibrosis, with clinical-stage candidates AP01 and AP02. The filing highlights the company's emerging growth status, reduced reporting requirements, and risks related to clinical trial outcomes, regulatory approvals, and market competition. The IPO proceeds will fund ongoing trials and commercialization efforts.

DRS filed

Avalyn Pharma Inc. is conducting an initial public offering (IPO) of its common stock, seeking to list on the Nasdaq Global Market under the symbol 'AVLN.' The company is a clinical-stage biopharmaceutical firm focused on developing inhaled therapies for rare respiratory diseases, including pulmonary fibrosis. Its pipeline includes AP01 and AP02, inhaled formulations of pirfenidone and nintedanib, which are in Phase 2 trials. Avalyn is an emerging growth company and smaller reporting company, with no prior public market for its stock. The offering includes underwriting discounts and a directed share program for insiders.